Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclophosphamide Anhydrous SCHEMBL28088100 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL7304 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL14192809 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4346 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL1285823 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL20542636 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4994883 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5802618 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL6071 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5436000 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-5658945-A | ANTICANCER AGENT; AIDS THERAPY; CONTROLLING INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5633280-A | ACCELERATED RECOVERY FROM CHEMOTHERAPY, RADIATION TREATMENT, BONE MARROW TRANSPLANTATION, INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5616612-A | THERAPY FOR CANCER, AIDS, ANEMIA, INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-04-01 | — | — | US | disclosed |
| US-5602275-A | MAY BE USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO- OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
| US-5545662-A | USED TO ACCELERATE RECOVERY FROM NEUTROPENIA ACCOMPANYING RADIO OR CHEMOTHERAPY, BONE MARROW TRANSPLANTATION, OR INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| US-5312831-A | Immunology, anticarcinogenic agents and AIDS treatment | AMERICAN CYANAMID COMPANY (US) | 1994-05-17 | — | — | US | disclosed |